May 2026 | Jack Overell, Head of Production, SAE Media Group

The recent Pre-Filled Syringes and Injectable Drug Devices East Coast Conferencebrought together experts from across the pharmaceutical, device, packaging, and regulatory ecosystem to examine how injectable drug delivery must evolve in response to increasingly complex therapies, new patient expectations, and shifting regulatory landscapes. Discussions across both the Focus Day and Main Conference reinforced a clear message: injectable drug delivery is no longer a linear or siloed activity, but a fully integrated, lifecycle-long system challenge.

From Strategy to Execution: Early Integration Is Critical

A recurring theme was the need to integrate device, packaging, formulation, and regulatory considerations far earlier in development than has traditionally been the case. Participants explored how early strategic foresight – through pipeline analysis, modality selection, and platform planning – can significantly reduce late stage risk. Device development was repeatedly positioned not as a downstream task, but as a core component of the therapeutic product itself.

Platform based approaches featured prominently, with discussions highlighting how established delivery platforms can accelerate development, enable data reuse, and support regulatory bridging strategies – provided they are accompanied by rigorous upfront planning, documentation discipline, and cross functional alignment.

Primary Packaging as a Strategic Foundation

The Main Conference placed particular emphasis on primary packaging, underscoring its role as the foundation upon which combination products are built. Early container choices were shown to have far-reaching implications for drug stability, device performance, patient experience, regulatory flexibility, and long term commercial viability.

Technical sessions explored the challenges associated with high concentration biologics and long shelf lives, including the impact of silicone aging in glass containers. While manageable, these risks require early, multi-method characterization and a holistic approach that considers formulation, container materials, coating technologies, and device requirements together. Advances in polymer based containers were also discussed, with speakers highlighting their growing maturity, robustness, and suitability for modern biologics.

Designing for Real World Use, Not Just Approval

Human factors and patient perspective emerged as central considerations – particularly beyond initial approval. Post-market insights were presented as a valuable but often underused resource, capable of revealing real-world use patterns, complaint drivers, and opportunities for targeted improvement without unnecessary disruption to marketed products.

Patient preference data shared during the conference reinforced that innovation alone does not guarantee adoption. Familiar formats continue to play a significant role, and user education, onboarding, and confidence building were identified as essential enablers for newer delivery technologies, including on body and near-body systems.

Regulatory Clarity and Evolving Expectations

Regulatory discussions highlighted increasing emphasis on clearly defining, validating, and controlling device performance characteristics that directly impact drug delivery throughout a product’s lifecycle. Risk-based strategies, realistic use conditions, and system-level evidence were consistently emphasized, alongside the importance of early and sustained dialogue with regulators – particularly when leveraging platforms, novel technologies, or bridging approaches.

Scaling for the Future

As biologics, gene therapies, and chronic disease treatments move toward higher volumes and broader patient populations, scalability and sustainability are becoming defining challenges. Sessions explored the trade-offs between single-use, multi-dose, and reusable systems, as well as the role of automation, platform devices, and global manufacturing networks in meeting future demand. Throughout, human-centred design remained a constant priority, even at scale.

Key Takeaways

Across the program, several consistent insights emerged:
 

• Injectable drug delivery must be treated as an integrated system across drug, device, packaging, and manufacturing
• Early alignment dramatically reduces technical, regulatory, and commercial risk
• Primary packaging decisions are strategic, not commodity choices
• Real-world use data and post market insights are critical to long-term success
• Regulatory clarity and patient confidence are as important as technical innovation

Looking Ahead

The PFS & IDD East Coast Conference made clear that the future of injectable drug delivery will be defined less by individual technologies and more by how effectively stakeholders collaborate across disciplines and across the product lifecycle. As therapies become more complex and patient expectations continue to rise, success will depend on system-level thinking, early integration, and a relentless focus on real world use.

Have a story that deserves industry attention?

We invite organizations, researchers, and solution providers to share news stories, press releases, and regulatory or clinical updates for consideration in the PFS & Injectable Drug Devices Newsletter.

Whether you’re announcing a clinical trial milestone, product launch, manufacturing innovation, regulatory approval, or strategic partnership, your news can reach a global audience of senior pharma, biotech, and industry decision makers.

Submit your stories to pfsnewsletter@saemediagroup.com and help keep the PFS & IDD community informed on the developments shaping the sector.